Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- Hitting Home Runs & Grand Slams, Not Loud Outs
- RTI: Do Stocks Tank When QE Ends?
- 3 Top-Ranked Consumer ETFs to Buy Now
- This Week's Aggressive Growth Stocks
- Who Wants to Keep "Too Big to Fail" Alive?
- Debt-Ceiling Alarm Bell Tolls
- Avoid These 3 Eurozone ETFs This Summer
- RTI: When Will We Finally See a Pullback?
- Top Stocks with Big Potential Catch-Up Moves
- AWS 5/22: Will Bernanke Show His Hand?
- PFP 5/22: Singular Stock Focus Continues
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/22/2013
| Company Name | Symbol | %Change |
|---|---|---|
| ALLIANCE FIB | AFOP | 9.31% |
| SONIC FOUNDR | SOFO | 7.77% |
| TRI TECH HOL | TRIT | 6.62% |
| A M R CP | AAMRQ | 4.52% |
| FLOWERS FOOD | FLO | 4.31% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
DARA Biosciences, Inc. ( DARA ) recently entered into an exclusive distribution agreement with Seyer Pharmatec Inc. to sell and distribute the breast cancer product Soltamox in the Commonwealth of Puerto Rico. The company intends to launch Soltamox later in the year.
Soltamox is the first and only oral liquid formulation for breast cancer to be approved by the US Food & Drug Administration (FDA). Soltamox is marketed in the US by DARA. License to sell Soltamox in the US was granted by Rosemont Pharmaceuticals.
We note that many patients suffering from breast cancer face problems in swallowing pills. So an oral liquid formulation will be a convenient, comfortable and easy-to-swallow alternative for women with breast cancer.
In January, this year DARA acquired South Carolina-based specialty pharmaceutical company, Oncogenerix, Inc. Oncogenerix held an exclusive license for the US marketing rights to Soltamox from Rosemont. After Oncogenerix’ acquisition DARA now enjoys the rights to market the product in the US. Rosemont markets Soltamox in the UK and Ireland.
We remind investors that in June, this year, DARA launched its first product Bionect which treats skin irritation and burns associated with radiation therapy. The company introduced the product for the cancer care market across the US.
An important oncology candidate at DARA is KRN5500 (completed phase IIa study). The company’s pipeline also includes DB959 (type 2 diabetes).
Our Recommendation
Currently, we have a Neutral long-term stance on DARA. The company carries a Zacks #3 Rank (Hold rating) in the short run.
Read the full on DARA